<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20488" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Diazepam</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dhaliwal</surname>
            <given-names>Jaberpreet S.</given-names>
          </name>
          <aff>Kaweah Delta Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rosani</surname>
            <given-names>Alan</given-names>
          </name>
          <aff>TTUHSC at the Permian Basin</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saadabadi</surname>
            <given-names>Abdolreza</given-names>
          </name>
          <aff>Western University/ Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jaberpreet Dhaliwal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alan Rosani declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20488.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Diazepam is a benzodiazepine medication that is FDA approved for the management of anxiety disorders, short-term relief of anxiety symptoms, spasticity associated with upper motor neuron disorders, adjunct therapy for muscle spasms, preoperative anxiety relief, management of certain refractory epilepsy patients, and adjunct in severe recurrent convulsive seizures, and an adjunct in status epilepticus. Off-label (non-FDA approved) use for diazepam includes sedation in the ICU and short-term treatment of spasticity in children with cerebral palsy. This activity will highlight the mechanism of action, adverse event profile, approved and off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions of diazepam, pertinent for interprofessional team members using diazepam for any of its intended indications.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for using diazepam.</p></list-item><list-item><p>Summarize the adverse effects of diazepam.</p></list-item><list-item><p>Review the mechanism of action of diazepam.</p></list-item><list-item><p>Outline the importance of improving care coordination among the interprofessional team to enhance the delivery of care for patients when using diazepam.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20488&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20488">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20488.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Diazepam is an anxiolytic benzodiazepine, first patented and marketed in the United States in 1963. It is a fast-acting, long-lasting benzodiazepine commonly used to treat anxiety disorders and alcohol detoxification, acute recurrent seizures, severe muscle spasms, and spasticity associated with neurologic disorders. In acute alcohol withdrawal, diazepam is useful for symptomatic relief of agitation, tremor, alcoholic hallucinosis, and acute delirium tremens.<xref ref-type="bibr" rid="article-20488.r1">[1]</xref>&#x000a0;Benzodiazepines have largely replaced barbiturates in treating anxiety and sleep disorders because of their improved safety profile, fewer side effects, and flumazenil(antagonist)&#x000a0;availability that can reverse oversedation&#x000a0;in cases of benzodiazepine intoxication.<xref ref-type="bibr" rid="article-20488.r2">[2]</xref><xref ref-type="bibr" rid="article-20488.r3">[3]</xref></p>
        <p>Diazepam is FDA approved for the management of anxiety disorders, short-term relief of anxiety symptoms, spasticity associated with upper motor neuron disorders, adjunct therapy for muscle spasms, preoperative anxiety relief, management of certain refractory epilepsy patients, and adjunct in severe recurrent convulsive seizures, and an adjunct in status epilepticus. Off-label (non-FDA approved) use for diazepam includes sedation in the ICU and short-term treatment of spasticity in children with cerebral palsy.<xref ref-type="bibr" rid="article-20488.r4">[4]</xref></p>
      </sec>
      <sec id="article-20488.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Benzodiazepines exert their effects by facilitating the activity of gamma-aminobutyric acid(GABA) at various sites.&#x000a0;Specifically, benzodiazepines bind at an allosteric site at the interface between the alpha and gamma subunits on&#x000a0;GABA-A&#x000a0;receptor chloride ion channels. The allosteric binding of diazepam at the&#x000a0;GABA-A&#x000a0;receptor increases the frequency at which the chloride channel opens, leading to an increased conductance of chloride ions. This&#x000a0;shift in charge leads to a&#x000a0;hyperpolarization of the neuronal membrane and reduced neuronal excitability.<xref ref-type="bibr" rid="article-20488.r5">[5]</xref></p>
        <p>Specifically, the allosteric binding within the limbic system leads to the anxiolytic effects seen with diazepam. Allosteric binding within the spinal cord and motor neurons is the primary mediator of the myorelaxant effects seen with diazepam. Mediation of the sedative, amnestic, and anticonvulsant effects of diazepam is through receptor binding within the cortex, thalamus, and cerebellum.<xref ref-type="bibr" rid="article-20488.r6">[6]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Absorption:&#x000a0;After oral administration of diazepam &#x0003e;90%&#x000a0; is absorbed, the average time to achieve peak plasma concentrations is 1&#x000a0;to 1.5 hours. Absorption is delayed and decreased when administered with a meal. There is an increase in the mean time to achieve peak concentrations to approximately 2.5 hours in the presence of food.&#x000a0;</p>
        <p>Distribution: Diazepam is highly lipophilic. While there is a moderately quick onset of action, the drug quickly redistributes.&#x000a0;Diazepam and its metabolites&#x000a0;have high plasma protein binding.(diazepam 98%). Diazepam and metabolites penetrate the blood-brain and placental barriers and are found in breast milk. The volume of distribution is 0.8 to 1.0 L/kg.&#x000a0;</p>
        <p>Metabolism: Diazepam&#x000a0;is mostly broken&#x000a0;down by the microsomal enzymes CYP2C19 and CYP3A4 enzymes to several active metabolites, mainly&#x000a0;desmethyldiazepam. Other minor active metabolites include oxazepam and temazepam. The average half-lives of oral diazepam and&#x000a0;desmethyldiazepam&#x000a0;are about 46 and 100 hours, respectively.<xref ref-type="bibr" rid="article-20488.r6">[6]</xref></p>
        <p>Excretion:&#x000a0;The initial distribution is followed by a prolonged terminal elimination(half-life ~ 48 hours). Additionally, the terminal elimination half-life of the active metabolite N-desmethyldiazepam is up to 100 hours. Diazepam and its metabolites are excreted predominantly in the urine. Diazepam accumulates upon multiple dosing; consequently, the terminal elimination half-life of diazepam is slightly prolonged.</p>
      </sec>
      <sec id="article-20488.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Diazepam is available in multiple formulations, including oral tablets, intramuscular injections (IM), intravenous injections (IV), or rectal gel. Oral tablets have a more reliable absorption and controlled release when compared to IM.&#x000a0;When administered intravenously, diazepam has an onset of action&#x000a0;within&#x000a0;1 to 3 minutes, while oral dosing onset ranges between 15 to 60 minutes. In addition, diazepam is long-lasting, with a duration of action of more than 12 hours.</p>
        <list list-type="bullet">
          <list-item>
            <p>Treatment of acute ethanol withdrawal: Initial dosing should be 10 mg IM or IV. If needed, a follow-up dose of 5 to 10 mg is permissible 3 to 4 hours later. If using the oral tablet, dosing is 10 mg every 6 to 8 hours within the first 24 hours, then&#x000a0;5mg&#x000a0;every 6 to 8 hours after that as needed.<xref ref-type="bibr" rid="article-20488.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of anxiety: 2 to 10 mg can be given orally 2 to 4 times daily. If given parentally, dosing can be 2 to 10 mg and repeated in 3 to 4 hours, if needed.<xref ref-type="bibr" rid="article-20488.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of muscle spasms: 2 to 10 mg can be given orally 3 to 4 times daily. If given parentally, an initial dose of&#x000a0;5 to 10 mg can be followed by another 5-10mg dose&#x000a0;in 3 to 4 hours, if necessary.<xref ref-type="bibr" rid="article-20488.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of preoperative anxiety: Dosing is 10 mg IM before&#x000a0;surgery.<xref ref-type="bibr" rid="article-20488.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>For sedation in the ICU:&#x000a0;Loading dose of 5 to 10 mg for initial administration, followed by a maintenance dose of 0.03 to 0.10 mg/kg every 0.5 to 6 hours. (Barr 2013)</p>
          </list-item>
          <list-item>
            <p>Treatment of seizures:&#x000a0;2 to 10 mg orally dosed 2 to 4 times daily as adjunctive maintenance therapy. Rectal gel 0.2mg/kg is an option for intermittent management of seizures.&#x000a0;It may be repeated&#x000a0;in 4 to 12 hours if needed. Do not exceed five uses per month or&#x000a0;more than&#x000a0;one&#x000a0;dose&#x000a0;every five days.</p>
          </list-item>
          <list-item>
            <p>Skeletal muscle relaxant:&#x000a0;2 to 10 mg, dosed 3 to 4 times daily as an adjunct therapy.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Treatment of status epilepticus: 0.15 to 0.20 mg/kg IV per dose and may&#x000a0;be repeated&#x000a0;once needed. Do not exceed 10 mg per single dose.&#x000a0;Rectal administration of 0.2 to 0.5 mg/kg administered one time. Do not exceed 20 mg per dose.<xref ref-type="bibr" rid="article-20488.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Use in Specific Patient Populations</bold>
</p>
        <p><bold>Patients with Renal impairment</bold>:&#x000a0;Clinicians&#x000a0;should exercise caution when prescribing diazepam to the&#x000a0;older population as they tend to have decreased renal function&#x000a0;and clearance; therefore, this population is at an increased risk of diazepam accumulation and its major metabolites. The recommendation is to limit the dosage to the smallest effective amount. Paradoxical reactions of CNS hyperactivity have also been reported when using benzodiazepines in the elderly, manifesting as hyperactivity, aggressive behavior, irritability, anxiety, and hallucinations. Discontinuation of diazepam is recommended if there is&#x000a0;a&#x000a0;presence of&#x000a0;paradoxical agitation.<xref ref-type="bibr" rid="article-20488.r11">[11]</xref><xref ref-type="bibr" rid="article-20488.r12">[12]</xref><xref ref-type="bibr" rid="article-20488.r13">[13]</xref></p>
        <p><bold>Patients with Hepatic Impairment:&#x000a0;</bold>In mild and moderate cirrhosis, the mean half-life of diazepam is increased. In addition, the volume of distribution also increases, and average clearance decreases by almost half. Mean half-life is also increased with hepatic fibrosis by approximately 90 hours, chronic active hepatitis by 60 hours, and acute viral hepatitis to about 74 hours.</p>
        <p><bold>Pregnancy Considerations:&#x000a0;</bold>Diazepam&#x000a0;is classified&#x000a0;as a former FDA pregnancy category D, indicating positive evidence of human fetal risk. Still, the benefits from use in pregnant women may be acceptable despite the risk. The use of diazepam and other benzodiazepines in pregnancy correlates with an increased risk of congenital malformations, premature birth, low birth weight, and other neurodevelopmental abnormalities. However, additional studies are needed to confirm.&#x000a0;Diazepam readily crosses the placental barrier, and use during pregnancy may result in neonatal withdrawal soon after birth. Symptoms of neonatal withdrawal include high-pitched cry, hypertonia, tremor, irritability,&#x000a0;feeding difficulties, sleep/wake&#x000a0;disturbances, gastrointestinal and autonomic disturbances, respiratory problems, and failure to thrive. The onset of withdrawal in a neonate whose mother has taken diazepam during the pregnancy could be anywhere from the first days of life to the first few weeks. During the last trimester of pregnancy, diazepam use can result in "floppy infant syndrome," characterized by hypotonia, hypothermia, lethargy, respiratory distress, and suckling difficulties.<xref ref-type="bibr" rid="article-20488.r14">[14]</xref><xref ref-type="bibr" rid="article-20488.r15">[15]</xref></p>
        <p><bold>Breastfeeding&#x000a0;Considerations:&#x000a0;</bold>Diazepam and its metabolites are excreted in breast milk and may affect the nursing infant. Some studies have shown diazepam's relative infant dose (RID) to be approximately 9%. The relative infant dose (RID) is the dose received via breast milk relative to the mothers. A relative dose below 10% is within an acceptable range regarded as reasonably safe in the short term. However, due to diazepam's long half-life, metabolites may accumulate in a breastfed infant. Therefore, the clinician should monitor an infant breastfed by a mother receiving diazepam for drowsiness, decreased feeding, lethargy, and failure to thrive. Discontinue breastfeeding in cases&#x000a0;with high doses of diazepam or when repeated administration will be necessary. However, when a single dose of diazepam is required for a procedure or seizure, the clinician should advise the mother to wait six to eight hours before resuming nursing, particularly with a preterm infant.<xref ref-type="bibr" rid="article-20488.r16">[16]</xref><xref ref-type="bibr" rid="article-20488.r17">[17]</xref></p>
      </sec>
      <sec id="article-20488.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Like most benzodiazepines, the adverse reactions of diazepam include CNS and respiratory depression, dependence,&#x000a0;and benzodiazepine withdrawal syndrome.<xref ref-type="bibr" rid="article-20488.r18">[18]</xref></p>
        <p>Serious adverse effects of diazepam include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Respiratory depression</p>
          </list-item>
          <list-item>
            <p>Suicidality<xref ref-type="bibr" rid="article-20488.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <p>Dependency and abuse</p>
          </list-item>
          <list-item>
            <p>Withdrawal symptoms</p>
          </list-item>
          <list-item>
            <p>Cardiovascular collapse</p>
          </list-item>
          <list-item>
            <p>Bradycardia&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hypotension</p>
          </list-item>
          <list-item>
            <p>Syncope</p>
          </list-item>
          <list-item>
            <p>Paradoxical CNS stimulation<xref ref-type="bibr" rid="article-20488.r20">[20]</xref></p>
          </list-item>
        </list>
        <p>Common adverse effects of diazepam include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Sedation</p>
          </list-item>
          <list-item>
            <p>Fatigue</p>
          </list-item>
          <list-item>
            <p>Confusion</p>
          </list-item>
          <list-item>
            <p>Anterograde amnesia</p>
          </list-item>
          <list-item>
            <p>Depression</p>
          </list-item>
          <list-item>
            <p>Ataxia</p>
          </list-item>
          <list-item>
            <p>Irritability</p>
          </list-item>
          <list-item>
            <p>Disinhibition</p>
          </list-item>
          <list-item>
            <p>Local injection site reaction</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Tremor</p>
          </list-item>
          <list-item>
            <p>Dystonia</p>
          </list-item>
          <list-item>
            <p>Urinary retention</p>
          </list-item>
          <list-item>
            <p>Incontinence</p>
          </list-item>
          <list-item>
            <p>Nausea</p>
          </list-item>
          <list-item>
            <p>Constipation</p>
          </list-item>
          <list-item>
            <p>Diplopia</p>
          </list-item>
          <list-item>
            <p>Libido changes</p>
          </list-item>
          <list-item>
            <p>Rash</p>
          </list-item>
          <list-item>
            <p>Menstrual irregularities</p>
          </list-item>
          <list-item>
            <p>ALT and/or AST elevation<xref ref-type="bibr" rid="article-20488.r21">[21]</xref></p>
          </list-item>
        </list>
        <p>Drug Interactions:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Potent inhibition of the CYP2C19 enzyme by certain drugs (fluoxetine and chloramphenicol) and CYP3A4 enzymes by certain medications (ketoconazole, protease inhibitors, erythromycin) may cause increased levels of diazepam.</p>
          </list-item>
          <list-item>
            <p>Inducers of CYP2C19 (rifampicin and prednisone) and CYP3A4 (carbamazepine,&#x000a0;topiramate, phenytoin, St. John's wort,&#x000a0;rifampin, or barbiturates) may cause lower levels.<xref ref-type="bibr" rid="article-20488.r22">[22]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20488.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications to diazepam include patients with a known hypersensitivity to diazepam. Diazepam is also contraindicated&#x000a0;in patients under six months of age. Other contraindications to diazepam include patients with severe respiratory insufficiency, myasthenia gravis, sleep apnea syndrome, and severe hepatic insufficiency. It is permissible in patients with open-angle glaucoma receiving appropriate therapy but&#x000a0;is contraindicated&#x000a0;in acute narrow-angle glaucoma.<xref ref-type="bibr" rid="article-20488.r23">[23]</xref><xref ref-type="bibr" rid="article-20488.r24">[24]</xref><bold>&#x000a0;</bold>The persistent and chronic use of benzodiazepines, including diazepam, can lead to physical dependence if used more frequently than recommended.<xref ref-type="bibr" rid="article-20488.r25">[25]</xref></p>
        <p>
<bold>US Boxed Warning</bold>
</p>
        <p>Simultaneous use of benzodiazepines and opioids may result in respiratory depression, profound sedation, coma, and death&#x02014;Reserve concomitant prescribing of these drugs for patients with inadequate alternative treatment options. Minimize&#x000a0;dose to the minimum to&#x000a0;prevent fatal respiratory depression.<xref ref-type="bibr" rid="article-20488.r26">[26]</xref></p>
      </sec>
      <sec id="article-20488.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Monitoring respiratory and cardiovascular status, blood pressure, heart rate, and anxiety symptoms in patients taking diazepam is crucial. With long-term use, monitor liver enzymes, CBC, and for signs of propylene glycol toxicity, including serum creatinine, BUN, serum lactate, and osmolality gap. With critically ill patients, monitor the depth of sedation.<xref ref-type="bibr" rid="article-20488.r27">[27]</xref></p>
        <p>Monitor&#x000a0;the patient for benzodiazepine use disorder (BUD)&#x000a0;and recommend appropriate referral. The use of mandatory prescription drug monitoring programs results in a substantial decrease in controlled substance prescriptions and misuse,&#x000a0;including opioids and benzodiazepines.<xref ref-type="bibr" rid="article-20488.r28">[28]</xref></p>
      </sec>
      <sec id="article-20488.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Diazepam Overdose</bold>
</p>
        <p>The toxic-to-therapeutic ratio of benzodiazepines is very&#x000a0;high, making them relatively safe medications. However, the potential of overdose from diverted diazepam always exists when combined with opioids, alcohol, or other centrally acting agents. Overdose in adults frequently involves the co-ingestion of other CNS depressants, which work synergistically to increase toxicity. In the case of single-agent diazepam overdose, symptoms manifest as CNS depression and are very&#x000a0;rarely fatal. In mild cases, lethargy, drowsiness, and confusion are common symptoms. In cases of severe overdose, symptoms manifest as ataxia, diminished reflexes, hypotonia, hypotension, respiratory depression, coma (rarely), and death (rarely).<xref ref-type="bibr" rid="article-20488.r14">[14]</xref></p>
        <p>Treatment of benzodiazepine overdose involves protecting the airway, fluid resuscitation, and the use of flumazenil if indicated. Flumazenil works via competitive antagonism at the benzodiazepine receptor and can rapidly reverse coma. However, in patients with benzodiazepine tolerance, flumazenil can precipitate acute withdrawal symptoms, autonomic instability, and seizures.<xref ref-type="bibr" rid="article-20488.r3">[3]</xref>&#x000a0;</p>
        <p>
<bold>Potential for Diazepam Abuse and Dependence</bold>
</p>
        <p>Diazepam is a Schedule IV controlled substance with&#x000a0;the potential for abuse. Development of dependence and tolerance can occur in addiction-prone, long-term treatment or those patients taking high doses. Thus, these individuals should be under careful supervision; once an individual develops dependence, the risk of developing withdrawal symptoms increases. Signs of benzodiazepine withdrawal include tremors,&#x000a0;rebound anxiety, perceptual disturbances, dysphoria, psychosis, agitation, irritability, restlessness, sweating, headache, confusion,&#x000a0;myalgias, abdominal pain, and vomiting. In long-term use and abrupt cessation, there is potential for hallucinations and epileptic seizures to occur.<xref ref-type="bibr" rid="article-20488.r29">[29]</xref><xref ref-type="bibr" rid="article-20488.r25">[25]</xref></p>
        <p>
<bold>Propylene Glycol Toxicity</bold>
</p>
        <p>Propylene glycol toxicity is a rare&#x000a0;toxidrome&#x000a0;associated with the parenteral use of diazepam. Propylene glycol is a common diluent used in the suspension of IV diazepam. Large doses or long-term infusions of IV diazepam can cause accumulation of propylene glycol and subsequent anion gap metabolic acidosis. Signs of propylene glycol poisoning include the development of serum hyperosmolality, hemolysis, cardiac dysrhythmias, hypotension, lactic acidosis, seizure, acute kidney injury, and multisystem organ failure.<xref ref-type="bibr" rid="article-20488.r30">[30]</xref></p>
      </sec>
      <sec id="article-20488.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Diazepam is a fast-acting potent anxiolytic popular due to its broad therapeutic index, low toxicity, and improved safety profile. Nonetheless, diazepam is still a drug with a high potential for use disorder associated with severe adverse/toxic effects. Therefore, clinicians should identify the proper indication for the prescription of diazepam. Psychiatrist consultation is necessary in the cases of anxiety disorders. Neurologists should&#x000a0;prescribe&#x000a0;diazepam in spasticity and status epilepticus, considering&#x000a0;the risk vs. benefit ratio for the individual patients. The pharmacists are responsible&#x000a0;for the proper dosing of diazepam, medication reconciliation, and patient counseling. The pharmacist should report to the clinician or nurse if there are significant interactions.<xref ref-type="bibr" rid="article-20488.r31">[31]</xref><xref ref-type="bibr" rid="article-20488.r32">[32]</xref></p>
        <p>In acute overdose of diazepam, triage nurses and emergency department physicians are responsible for rapid diagnosis and stabilization of the patient. Critical care physicians should manage respiratory depression, which can be life-threatening if not treated promptly. In ICU,&#x000a0;regular assessment of RASS(Richmond agitation-sedation scale) and CAM-ICU (confusion assessment method for the ICU) scoring should guide the proper use of sedatives. Consulting the psychiatrist is especially&#x000a0;important&#x000a0;if the diazepam overdose is intentional.<xref ref-type="bibr" rid="article-20488.r33">[33]</xref></p>
        <p>A randomized controlled trial, EMPOWER (Eliminating Medications Through Patient Ownership of End Results), for reducing inappropriate benzodiazepine prescriptions&#x000a0;for&#x000a0;older adults through direct patient education was conducted to compare the result of a direct-to-consumer educational intervention against usual care on benzodiazepine discontinuation in older adults. At the end of six months, 27% of the intervention group discontinued benzodiazepine compared to 5% in the control group using the stepwise tapering protocol.<xref ref-type="bibr" rid="article-20488.r34">[34]</xref>&#x000a0;[Level 1]</p>
        <p>As illustrated above,&#x000a0;managing patients on&#x000a0;diazepam requires an interprofessional team approach consisting of clinicians (MDs, DOs, NPs, PAs), specialists, nurses, pharmacists, and other healthcare providers. As stated previously, prescribing&#x000a0;clinicians should&#x000a0;be responsible for&#x000a0;checking&#x000a0;state and federal controlled substance databases to detect benzodiazepine use disorder, diversion, and prevent improper drug use.<xref ref-type="bibr" rid="article-20488.r28">[28]</xref>&#x000a0;An interprofessional team approach would achieve maximum efficacy and minimize potential adverse drug reactions for the patients requiring diazepam, which can&#x000a0;translate to better patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-20488.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20488&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20488">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20488/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20488">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-20488.s11">
        <fig id="article-20488.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Chemical Structure of Diazepam Contributed by US National Library of Medicine</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Diazepam__Structure__-__NIH" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-20488.s12">
        <title>References</title>
        <ref id="article-20488.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calcaterra</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Barrow</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Classics in chemical neuroscience: diazepam (valium).</article-title>
            <source>ACS Chem Neurosci</source>
            <year>2014</year>
            <month>Apr</month>
            <day>16</day>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>253</fpage>
            <page-range>253-60</page-range>
            <pub-id pub-id-type="pmid">24552479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Sharbaf Shoar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bistas</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Saadabadi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Flumazenil</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>23</day>
            <pub-id pub-id-type="pmid">29262246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>An</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Godwin</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Flumazenil in benzodiazepine overdose.</article-title>
            <source>CMAJ</source>
            <year>2016</year>
            <month>Dec</month>
            <day>06</day>
            <volume>188</volume>
            <issue>17-18</issue>
            <fpage>E537</fpage>
            <pub-id pub-id-type="pmid">27920113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weintraub</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Diazepam in the Treatment of Moderate to Severe Alcohol Withdrawal.</article-title>
            <source>CNS Drugs</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>87</fpage>
            <page-range>87-95</page-range>
            <pub-id pub-id-type="pmid">28101764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nutt</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Malizia</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder.</article-title>
            <source>Br J Psychiatry</source>
            <year>2001</year>
            <month>Nov</month>
            <volume>179</volume>
            <fpage>390</fpage>
            <page-range>390-6</page-range>
            <pub-id pub-id-type="pmid">11689393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Friedman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Greenblatt</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Metzler</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Charlton</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Harmatz</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Antal</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Sanborn</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Francom</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1992</year>
            <month>Aug</month>
            <volume>52</volume>
            <issue>2</issue>
            <fpage>139</fpage>
            <page-range>139-50</page-range>
            <pub-id pub-id-type="pmid">1505149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vinkers</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Tijdink</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Luykx</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Vis</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>[Choosing the correct benzodiazepine: mechanism of action and pharmacokinetics].</article-title>
            <source>Ned Tijdschr Geneeskd</source>
            <year>2012</year>
            <volume>155</volume>
            <issue>35</issue>
            <fpage>A4900</fpage>
            <pub-id pub-id-type="pmid">22929751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <chapter-title>Benzodiazepines</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>1</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">31643621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pekcan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Celebioglu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Demir</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Saricaoglu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hascelik</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yukselen</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Basgul</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Aypar</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>The effect of premedication on preoperative anxiety.</article-title>
            <source>Middle East J Anaesthesiol</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>421</fpage>
            <page-range>421-33</page-range>
            <pub-id pub-id-type="pmid">16438017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crawshaw</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Cock</surname>
                <given-names>HR</given-names>
              </name>
            </person-group>
            <article-title>Medical management of status epilepticus: Emergency room to intensive care unit.</article-title>
            <source>Seizure</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>75</volume>
            <fpage>145</fpage>
            <page-range>145-152</page-range>
            <pub-id pub-id-type="pmid">31722820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <collab>By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>63</volume>
            <issue>11</issue>
            <fpage>2227</fpage>
            <page-range>2227-46</page-range>
            <pub-id pub-id-type="pmid">26446832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vozeh</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>[Pharmacokinetic of benzodiazepines in old age].</article-title>
            <source>Schweiz Med Wochenschr</source>
            <year>1981</year>
            <month>Nov</month>
            <day>21</day>
            <volume>111</volume>
            <issue>47</issue>
            <fpage>1789</fpage>
            <page-range>1789-93</page-range>
            <pub-id pub-id-type="pmid">6118950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <collab>By the 2019 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2019 Updated AGS Beers Criteria&#x000ae; for Potentially Inappropriate Medication Use in Older Adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>674</fpage>
            <page-range>674-694</page-range>
            <pub-id pub-id-type="pmid">30693946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bellantuono</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tofani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Di Sciascio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Santone</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview.</article-title>
            <source>Gen Hosp Psychiatry</source>
            <year>2013</year>
            <season>Jan-Feb</season>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-8</page-range>
            <pub-id pub-id-type="pmid">23044244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dallmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ince</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Coboeken</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eissing</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hempel</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>57</volume>
            <issue>6</issue>
            <fpage>749</fpage>
            <page-range>749-768</page-range>
            <pub-id pub-id-type="pmid">28924743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brandt</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Passage of diazepam and desmethyldiazepam into breast milk.</article-title>
            <source>Arzneimittelforschung</source>
            <year>1976</year>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>454</fpage>
            <page-range>454-7</page-range>
            <pub-id pub-id-type="pmid">989345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r17">
          <label>17</label>
          <element-citation publication-type="book">
            <chapter-title>Diazepam</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seldenrijk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Henstra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ho Pian</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>van Grootheest</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Salomons</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Overmeire</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>de Boer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scheers</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Doornebal-Bakker</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ruh&#x000e9;</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Vinkers</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>[Systematic review of the side effects of benzodiazepines].</article-title>
            <source>Ned Tijdschr Geneeskd</source>
            <year>2017</year>
            <volume>161</volume>
            <fpage>D1052</fpage>
            <pub-id pub-id-type="pmid">29076441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dodds</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Prescribed Benzodiazepines and Suicide Risk: A Review of the Literature.</article-title>
            <source>Prim Care Companion CNS Disord</source>
            <year>2017</year>
            <month>Mar</month>
            <day>02</day>
            <volume>19</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">28257172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mancuso</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Tanzi</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Gabay</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Paradoxical reactions to benzodiazepines: literature review and treatment options.</article-title>
            <source>Pharmacotherapy</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>9</issue>
            <fpage>1177</fpage>
            <page-range>1177-85</page-range>
            <pub-id pub-id-type="pmid">15460178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r21">
          <label>21</label>
          <element-citation publication-type="book">
            <chapter-title>Diazepam (Oral)</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>22</day>
            <pub-id pub-id-type="pmid">31643207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ning</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Huo</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects.</article-title>
            <source>Toxicol Lett</source>
            <year>2018</year>
            <month>Sep</month>
            <day>15</day>
            <volume>294</volume>
            <fpage>27</fpage>
            <page-range>27-36</page-range>
            <pub-id pub-id-type="pmid">29753067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Son</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Namkoong</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Association between use of benzodiazepines and occurrence of acute angle-closure glaucoma in the elderly: A population-based study.</article-title>
            <source>J Psychosom Res</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>122</volume>
            <fpage>1</fpage>
            <page-range>1-5</page-range>
            <pub-id pub-id-type="pmid">31126405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Kao</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepines Associated With Acute Respiratory Failure in Patients With Obstructive Sleep Apnea.</article-title>
            <source>Front Pharmacol</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>1513</fpage>
            <pub-id pub-id-type="pmid">30666205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soyka</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Benzodiazepine Dependence.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Mar</month>
            <day>23</day>
            <volume>376</volume>
            <issue>12</issue>
            <fpage>1147</fpage>
            <page-range>1147-1157</page-range>
            <pub-id pub-id-type="pmid">28328330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McClure</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Niles</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Gudin</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Concurrent Use of Opioids and Benzodiazepines: Evaluation of Prescription Drug Monitoring by a United States Laboratory.</article-title>
            <source>J Addict Med</source>
            <year>2017</year>
            <season>Nov/Dec</season>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>420</fpage>
            <page-range>420-426</page-range>
            <pub-id pub-id-type="pmid">28953504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ku</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Hornik</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Beechinor</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Chamberlain</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Guptill</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Capparelli</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Martz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Anand</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cohen-Wolkowiez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>D</given-names>
              </name>
              <collab>Best Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee</collab>
            </person-group>
            <article-title>Population Pharmacokinetics and Exploratory Exposure-Response Relationships of Diazepam in Children Treated for Status Epilepticus.</article-title>
            <source>CPT Pharmacometrics Syst Pharmacol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>7</volume>
            <issue>11</issue>
            <fpage>718</fpage>
            <page-range>718-727</page-range>
            <pub-id pub-id-type="pmid">30267478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manders</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Abd-Elsayed</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Mandatory Review of Prescription Drug Monitoring Program Before Issuance of a Controlled Substance Results in Overall Reduction of Prescriptions Including Opioids and Benzodiazepines.</article-title>
            <source>Pain Physician</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>299</fpage>
            <page-range>299-304</page-range>
            <pub-id pub-id-type="pmid">32517396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brett</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Murnion</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Management of benzodiazepine misuse and dependence.</article-title>
            <source>Aust Prescr</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>38</volume>
            <issue>5</issue>
            <fpage>152</fpage>
            <page-range>152-5</page-range>
            <pub-id pub-id-type="pmid">26648651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jahn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bodreau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Farthing</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Elbarbry</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Assessing Propylene Glycol Toxicity in Alcohol Withdrawal Patients Receiving Intravenous Benzodiazepines: A One-Compartment Pharmacokinetic Model.</article-title>
            <source>Eur J Drug Metab Pharmacokinet</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>423</fpage>
            <page-range>423-430</page-range>
            <pub-id pub-id-type="pmid">29392569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaccara</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Giannasi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Oggioni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rosati</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tramacere</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Palumbo</surname>
                <given-names>P</given-names>
              </name>
              <collab>convulsive status epilepticus study group of the uslcentro Toscana, Italy</collab>
            </person-group>
            <article-title>Challenges in the treatment of convulsive status epilepticus.</article-title>
            <source>Seizure</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>47</volume>
            <fpage>17</fpage>
            <page-range>17-24</page-range>
            <pub-id pub-id-type="pmid">28282553</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mekonnen</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>McLachlan</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Brien</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of pharmacist-led medication reconciliation programmes on clinical outcomes at hospital transitions: a systematic review and meta-analysis.</article-title>
            <source>BMJ Open</source>
            <year>2016</year>
            <month>Feb</month>
            <day>23</day>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>e010003</fpage>
            <pub-id pub-id-type="pmid">26908524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taran</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Namadian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Faghihzadeh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Naghibi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The Effect of Sedation Protocol Using Richmond Agitation-Sedation Scale (RASS) on Some Clinical Outcomes of Mechanically Ventilated Patients in Intensive Care Units: a Randomized Clinical Trial.</article-title>
            <source>J Caring Sci</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>199</fpage>
            <page-range>199-206</page-range>
            <pub-id pub-id-type="pmid">31915621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20488.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tannenbaum</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tamblyn</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Benedetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial.</article-title>
            <source>JAMA Intern Med</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>174</volume>
            <issue>6</issue>
            <fpage>890</fpage>
            <page-range>890-8</page-range>
            <pub-id pub-id-type="pmid">24733354</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
